Brian Armstrong announced a dinner next month in Boston, inviting scientists and engineers from the fields of neuroscience, genetics, drug development, computational biology, or machine learning to discuss how to safely enhance human intelligence. The topics will also cover treatments for cognitive disorders and ways to help healthy adults learn faster, reason better, and solve more difficult problems.

He emphasized that there are still many unknowns: which paths are feasible, which are safe, especially for effective solutions for adults. If a suitable founding team emerges from the discussions, he intends to provide funding support. Those unable to attend in person can join online, with travel expenses reimbursable, and registration can be done through the application link he published.

This continues his recent practice of using dinners to facilitate biotech startups. He has self-funded the research paper platform ResearchHub and co-founded NewLimit, which focuses on epigenetic reprogramming to delay aging. Previously, he hosted a dinner on embryo editing in the Bay Area, stating that approximately 400 million people worldwide are affected by genetic diseases, and expressed willingness to invest if a team is formed. In public interviews, he has discussed nutrients and child development, as well as whether therapies should be applied to level cognitive baselines, stating that humanity needs to master its own evolution as artificial intelligence becomes stronger.

The dinner places treatment and enhancement at the same table, clearly leaning towards interventions that can be effective in adults, rather than only discussing embryos or children. The participation threshold is relevant frontline work or expertise, rather than an open roadshow.

In market mechanisms, this is a founder selection market: the buyers are scientists looking to form teams, and the sellers are crypto-rich individuals willing to cover travel expenses and commit checks. Funds have not yet entered the new company, but will first go towards airfare and one night of interdisciplinary dialogue. Beneficiaries are laboratories lacking startup capital but having hypotheses for adult cognitive interventions; the pressured parties are traditional pharmaceutical companies that view enhancement as an ethical no-go zone. The event is driven by a public call, not by drug applications.

Cognition is being written as an investable infrastructure, placed alongside exchanges on the same personal balance sheet.

Source: Public Information